Elevance Health joins legal fight over Medicare Advantage Star Ratings
Elevance Health has entered the widening legal challenge to the federal government’s 2027 Medicare Advantage Star Ratings. The move places the insurer alongside peers that are contesting how those ratings were set and what they mean for plans competing in Medicare Advantage.
The lawsuit does not turn on a new clinical intervention or a drug trial. It turns on the machinery that now shapes a large share of Medicare Advantage business: quality scores that influence reputation, payment, and market position. In that sense, the case is about more than administrative process. It reaches into how insurers are judged on the care experience they are supposed to deliver to older adults and people with disabilities.
The Star Ratings program has long acted as a blunt instrument in managed care. Plans that score well gain leverage; plans that score poorly face pressure that can quickly become financial. For insurers, the stakes are obvious. For patients, the more subtle consequence is that quality measurement can influence benefit design, network decisions, and the resources plans devote to prevention, chronic disease management, and customer service. When a plan sues over those ratings, it is challenging not only a score but the framework that converts quality measurement into business consequence.
One sentence captures the entire dispute: the ratings now carry enough economic force to trigger litigation.
Why the 2027 rating cycle matters to Medicare Advantage plans
Medicare Advantage already depends on metrics that try to translate care quality into a single performance signal. That is a difficult task even under ideal conditions. Measures must account for preventive care, adherence, patient experience, follow-up after hospitalization, medication use, and the ordinary friction that comes with treating older patients with multiple chronic illnesses. Each component can be clinically meaningful on its own, but the scoring system compresses those details into an overall judgment that affects the plan far beyond the exam room.
For insurers, a disputed rating cycle can become a proxy fight over methodology, timing, and regulatory discretion. Plans often argue that a change in scoring rules, weighting, or data interpretation can distort performance from one year to the next. Regulators, in turn, defend the ratings as a tool to steer beneficiaries toward higher-quality coverage and to push plans toward better outcomes. The legal conflict emerges when those two positions collide: one side sees accountability, the other sees an uneven field.
The current lawsuit also signals how central Star Ratings have become to Medicare Advantage strategy. These ratings are no longer a side issue buried in compliance departments. They influence operating priorities, because plans that want to preserve competitive standing must constantly invest in performance improvement, outreach, and documentation. A score that slips can reverberate through enrollment patterns and corporate planning long after the measurement year has ended.
Quality measurement is shaping insurance behavior far beyond reimbursement
The dispute lands at a moment when managed care companies are already under pressure from regulators, investors, and members to justify how they deliver value. Quality scores are supposed to reward measurable care improvement. In practice, they also become a battleground over how complicated health care should be translated into a grade.
That tension is especially sharp in Medicare Advantage, where the populations served often have extensive chronic disease burdens and frequent interactions with the health system. A rating framework has to account for whether patients obtain recommended care, whether medications are filled and continued, whether follow-up happens after acute events, and whether the plan makes navigation easier or harder. Small differences in performance across these domains can have an outsized effect on the final score.
The legal challenge from Elevance Health suggests the company believes the 2027 system crosses a line, though the filing details are not laid out here. Still, the decision to sue is itself revealing. Insurers generally do not take on the federal government lightly in a program as commercially important as Medicare Advantage. Litigation usually means the plan believes the stakes are high enough, and the administrative path narrow enough, that court intervention could matter.
Patients rarely see the score, but they feel the consequences
Beneficiaries may never look up a Star Rating before choosing coverage. They still live with the downstream effects. A plan trying to improve its standing may intensify care management, invest in outreach, or refine how it tracks preventive services and medication adherence. A plan under pressure may also become more aggressive about documentation and data capture, because the scoring system rewards what can be counted.
The clinical relevance lies there. Better measurement can pull attention toward blood pressure control, diabetes care, vaccines, cancer screening, and follow-up after discharge. Poorly calibrated measurement can also distort priorities, encouraging plans to chase metrics that are easier to improve on paper while leaving harder access problems unresolved. The central question is whether the rating model encourages better care or simply better scorekeeping.
The fight over the 2027 ratings will therefore be read in two registers at once: as an insurance industry dispute and as a test of how much trust remains in the federal system that grades Medicare Advantage plans. If more insurers join the challenge, the ratings process could face growing legal and political scrutiny. If the courts uphold the government’s approach, plans will have to adapt to the current framework rather than challenge it.
For now, Elevance Health’s lawsuit adds another defendant to a familiar conflict, with the 2027 ratings sitting squarely at the center of Medicare Advantage competition and regulatory oversight.